No-Reflow Clinical Trials

6 recruitingLast updated: June 18, 2026

There are 6 actively recruiting no-reflow clinical trials across 5 countries. Studies span Phase 4, Not Applicable, Phase 2, Phase 3. Top locations include Cairo, Egypt, Kafr ash Shaykh, Kafrelsheikh, Egypt, Karachi, Sindh, Pakistan. Updated daily from ClinicalTrials.gov.


No-Reflow Trials at a Glance

6 actively recruiting trials for no-reflow are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Phase 4 with 2 trials, with the heaviest enrollment activity in Cairo, Kafr ash Shaykh, and Karachi. Lead sponsors running no-reflow studies include Ain Shams University, Instituto Nacional de Cardiologia Ignacio Chavez, and Kafrelsheikh University.

Browse no-reflow trials by phase

Treatments under study

About No-Reflow Clinical Trials

Looking for clinical trials for No-Reflow? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new No-Reflow trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about No-Reflow clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 4

Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention

Acute Myocardial InfarctionST-segment elevation myocardial infarction (STEMI)No-Reflow Phenomenon+1 more
National Institute of Cardiovascular Diseases, Pakistan1,148 enrolled2 locationsNCT07536802
Recruiting

Investigation of Brain Blood Flow Changes in Acute Ischemic Stroke Patients After Successful Endovascular Thrombectomy

ThrombectomyAcute Cerebrovascular AccidentNo-Reflow Phenomenon+1 more
University of Zurich100 enrolled1 locationNCT07534319
Recruiting
Not Applicable

No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track

STEMINo-ReflowIntracoronary+1 more
Kafrelsheikh University60 enrolled1 locationNCT06966674
Recruiting
Phase 3

The Investigator Administers Intracoronary Adrenaline Via the Catheter in STEMI Patients During Primary PCI, After Flow Restoration and Before Stenting, and Studies Its Effect in Prevention of No Reflow

ST-segment elevation myocardial infarction (STEMI)No-Reflow Phenomenon
Ain Shams University1,000 enrolled1 locationNCT06847568
Recruiting
Phase 2

Empagliflozin for No-reflow Phenomenon in PCI for STEMI

STEMINo-Reflow Phenomenon
Instituto Nacional de Cardiologia Ignacio Chavez162 enrolled1 locationNCT06342141
Recruiting
Phase 4

A Study to Evaluate the Impact of Pre-procedural Intracoronary Nicorandil Injection to PREVENT ReductioN of DecREased TIMI FLOW in Patients Who Undergoing Percutaneous Coronary Intervention for the Coronary Artery Disease

Coronary Artery DiseasePercutaneous Coronary InterventionNo-Reflow Phenomenon
Korea University Anam Hospital460 enrolled1 locationNCT05427786